Q-omics provides the consensus-scored ARHGAP27 profile across patient tissues and cancer cell-line models. ARHGAP27 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ARHGAP27 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, ARHGAP27 RNA expression shows 19,913 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRP, and UVM as cancer lineages where ARHGAP27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP27 survival associations across molecular data types. ARHGAP27 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP27 RNA expression–survival associations across cancer types. High ARHGAP27 expression shows unfavorable associations in ACC, UVM and LGG, but favorable associations in BLCA, SKCM and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for ARHGAP27 RNA expression.
This table summarizes ARHGAP27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP27 shows higher tumor expression in KIRP, KIRC, THCA, CHOL, BLCA and STAD. The KIRP box plot shows higher ARHGAP27 RNA expression in tumor versus normal tissue (log2 FC = +1.380, t-test p < 0.001).
This table shows molecular features associated with ARHGAP27 in patient tissues and cancer cell lines. In patient samples, ARHGAP27 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
